DK3182980T3 - Behandling af glykosyleringsmangelsygdomme - Google Patents
Behandling af glykosyleringsmangelsygdomme Download PDFInfo
- Publication number
- DK3182980T3 DK3182980T3 DK15833822.8T DK15833822T DK3182980T3 DK 3182980 T3 DK3182980 T3 DK 3182980T3 DK 15833822 T DK15833822 T DK 15833822T DK 3182980 T3 DK3182980 T3 DK 3182980T3
- Authority
- DK
- Denmark
- Prior art keywords
- glycosyling
- treatment
- deficiency diseases
- deficiency
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462039052P | 2014-08-19 | 2014-08-19 | |
PCT/US2015/045896 WO2016028894A1 (en) | 2014-08-19 | 2015-08-19 | Treatment of glycosylation deficiency diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3182980T3 true DK3182980T3 (da) | 2021-01-11 |
Family
ID=55351228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15833822.8T DK3182980T3 (da) | 2014-08-19 | 2015-08-19 | Behandling af glykosyleringsmangelsygdomme |
Country Status (6)
Country | Link |
---|---|
US (2) | US20170209476A1 (da) |
EP (1) | EP3182980B1 (da) |
DK (1) | DK3182980T3 (da) |
ES (1) | ES2841745T3 (da) |
PL (1) | PL3182980T3 (da) |
WO (1) | WO2016028894A1 (da) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020013342A2 (pt) * | 2018-02-01 | 2020-12-01 | Wellstat Therapeutics Corporation | composições e dispositivos para fornecimento sistêmico de uridina |
EP4190334A1 (en) * | 2018-06-14 | 2023-06-07 | Mayo Foundation for Medical Education and Research | Methods and materials for treating glycosylation disorders |
WO2022056428A1 (en) * | 2020-09-14 | 2022-03-17 | Wellstat Therapeutics Corporation | 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1171137E (pt) * | 1999-02-23 | 2008-03-17 | Univ California | Utilização de triacetiluridina para o tratamento de perturbações mitocondriais |
WO2007064691A1 (en) * | 2005-12-02 | 2007-06-07 | Nabil Habib Lab | Treatment of cancer and other diseases |
US20120078529A1 (en) * | 2009-05-13 | 2012-03-29 | Wellstat Therapeutics Corporation | Determining the severity of 5-fluorouracil overdose |
US20110257233A1 (en) * | 2010-03-19 | 2011-10-20 | Sanford-Burnham Medical Research Institute | Benzoisothiazolones as inhibitors of phosphomannose isomerase |
JP2015503924A (ja) * | 2012-01-05 | 2015-02-05 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | 遺伝子導入のための方法及び組成物 |
-
2015
- 2015-08-19 EP EP15833822.8A patent/EP3182980B1/en not_active Not-in-force
- 2015-08-19 US US15/329,647 patent/US20170209476A1/en active Pending
- 2015-08-19 WO PCT/US2015/045896 patent/WO2016028894A1/en active Application Filing
- 2015-08-19 ES ES15833822T patent/ES2841745T3/es active Active
- 2015-08-19 PL PL15833822T patent/PL3182980T3/pl unknown
- 2015-08-19 DK DK15833822.8T patent/DK3182980T3/da active
-
2022
- 2022-02-09 US US17/667,703 patent/US20220273688A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3182980A1 (en) | 2017-06-28 |
US20220273688A1 (en) | 2022-09-01 |
EP3182980B1 (en) | 2020-10-14 |
US20170209476A1 (en) | 2017-07-27 |
PL3182980T3 (pl) | 2021-04-19 |
EP3182980A4 (en) | 2018-06-06 |
WO2016028894A1 (en) | 2016-02-25 |
ES2841745T3 (es) | 2021-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
HK1247835A1 (zh) | 甲狀旁腺功能減退症的治療 | |
DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
PL3283527T3 (pl) | Leczenie skojarzone nowotworów | |
DK3450553T3 (da) | Mrna-terapi til behandling af øjensygdomme | |
DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
HUE056287T2 (hu) | Pancreatitis kezelése | |
DK3169328T3 (da) | Quinolinderivater til behandling af inflammationssygdomme | |
DK3231444T3 (da) | Ny behandling | |
DK3132009T3 (da) | Fremgangsmåde | |
DK3307267T3 (da) | Behandling af multipel sklerose | |
EP3375108A4 (en) | SELECTIVE WIFI | |
PL3393468T3 (pl) | Metody leczenia niedoboru odporności | |
DK3283210T3 (da) | Fremgangsmåde | |
DK3237621T5 (da) | Varianter af human alpha-galactosidase | |
LT3119384T (lt) | Intrahepatinių cholestazinių ligų gydymas | |
DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
IL257764B (en) | Methods for treatment of diseases | |
DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
DK3368044T3 (da) | Behandling af hepatisk steatose-relateret oligo-ovulation | |
DK3151814T3 (da) | Behandling af en hudlæsion | |
DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
DK2897382T3 (da) | Forbedring af binaural kilde |